Data investigation

What the FDA's GLP-1 Warning Letters Say About This Market

Two letters in 2023, ten in 2024, 72 in 2025. The most common subject is unlawful sale to consumers: enforcement here is overwhelmingly about what sellers said, not what pharmacies made.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·3 citations

We keep a register of FDA warning letters relevant to this market: 157 of them at our last count, on September 30, 2026. Read by year, it describes a regulator that went from occasional interest to sustained enforcement in about eighteen months: two letters in 2023, ten in 2024, 72 in 2025, and 73 in 2026 through mid-September, with the year not finished.

Enforcement did not stop at our count. FDA has since posted two more GLP-1 letters, dated September 23 and 24, 2026, each to a website it says was introducing unapproved and misbranded injectable semaglutide into interstate commerce.[2][3] Neither is in the figures below. Both fit the pattern they describe.

What the letters are about

Most common subjects across 157 letters in our enforcement register.
SubjectLetters
Unlawful sale of unapproved and misbranded drugs to US consumers54
False and misleading claims / misbranded34
False and misleading claims / misbranded (telehealth)25
Compounded GLP-1 marketing and labeling concerns12
Compounding pharmacy / adulterated drug products8

The distribution is the interesting part. The single most common category is selling (unlawful sale of unapproved and misbranded drugs to consumers), not manufacturing failure. Add the two misbranding categories and the marketing one, and the overwhelming majority of enforcement in this market is about what sellers said rather than what pharmacies made. Research-chemical peptide sites are a clear case: FDA’s letters to peptide sellers quote their disclaimers and set them aside.

Fifty-four letters concern unlawful sale to consumers. Eight concern adulterated products from compounding pharmacies.

That matches what we find reading seller sites, and it matters to a buyer: the failure this market is being disciplined for is claims, not contamination. Our articles on checking a review score and what a badge tells you cover the consumer end of the same problem.

Reading the letters to sellers in our register shows how specific the claims cases are. MyStart Health, TRYM Health and Tuyo Health each received an FDA warning letter over false or misleading claims about compounded GLP-1s on their own websites. The letter to Lyfe Rx quotes “Clinically Proven Weight Loss” as a claim that implied its compounded products were the same as approved drugs. Zeuss and Harper Meds were each cited for product labels bearing their own name, as if they had compounded the drug.

Bioverse is another seller in the register with a letter of its own: the FDA reviewed its website and found its claims about compounded semaglutide and tirzepatide false or misleading.

The wording FDA objects to also turns up on sites that have no letter. The semaglutide FAQ at Madison Meds says its compounded drug “contains the same active ingredient as Ozempic”, the phrasing FDA cited in 2025 letters to other sellers. Skinny Me America calls its custom-blended semaglutide with B6 and B12 “FDA-approved”. A homepage badge at Tennessee Trim Clinic calls its compounded medications “FDA-Approved” too, and Your Infinity Health says its compounded GLP-1s are produced in “FDA approved facilities”.

MEDVi has one too. The FDA said the labels pictured on its website implied that MEDVi compounds the drugs itself, which it does not.

The pharmacy letters read differently. The one sent to Empower Pharmacy, a Houston compounder that supplies clinics and telehealth sellers, followed an inspection of its 503A facility and found compounded drugs that were essentially copies of commercially available products, tirzepatide and semaglutide among them, along with production deficiencies. That is a statement about what was made, not what was said.

How many of them are sellers you could buy from

Fifty-seven of the 157 letters are matched to a seller we review. They cover 57 sellers, run by 54 operating companies, and five of those sellers have since closed. That is roughly one in eleven of the sellers we track: a meaningful minority, not a fringe.

A letter discloses a problem. It does not disqualify a seller. A warning letter is the FDA telling a company to fix something, not a finding that its product harmed anyone, and companies do fix things. What a letter gives you is a specific, dated, official account of what the agency objected to, which is far more useful than a rating. Read what it alleges, then decide.

An error of our own, in the same data

While assembling these figures we found that four of our own seller reviews were stating “4”, “5” and “6 FDA warning letters matched to this operator”, and that none of those four companies had a single letter in the register.

The cause was mundane and the consequence was not. The field holding letters had also been used, historically, to store general FDA-related notes: boilerplate along the lines of “compounded semaglutide is not FDA-approved and has not been evaluated by FDA”, which is true of every compounded product and is not a letter. The page counted the length of that list. Four named businesses were publicly credited with enforcement history they do not have.

It is corrected, an automated check now fails our build if a letter count is ever built from anything other than a letter, and we confirmed the fix did not create the opposite error. Those four reviews now say the company has no letter, which is true of them in the register. We are describing it here because an article about other people’s enforcement records that quietly omitted our own mistake would not be worth publishing.

How to read a letter if your seller has one

  1. Check the date. A 2023 letter about claims that have since changed is a different thing from one issued last quarter.
  2. Read the subject line. “Adulterated drug products” and “false and misleading claims” are not the same order of concern.
  3. Check who it was addressed to. Letters go to legal entities, which frequently operate several consumer brands (see who actually runs your brand). The letter about Fifty 410, for example, is addressed to its operator, Aspen Aesthetics.
  4. Look for what changed afterward. The point of a warning letter is compliance, and the useful question is whether the company complied.
  5. Read it yourself. Every letter is published by the FDA, and our warning letters page links each one to its source.

Frequently Asked Questions

Our register held 157 at its last count, on September 30, 2026. By year: two in 2023, ten in 2024, 72 in 2025 and 73 in 2026 through mid-September. FDA has issued more since, including two GLP-1 letters to websites selling injectable semaglutide, dated September 23 and 24, 2026. Enforcement went from occasional to sustained in about eighteen months.
Selling and saying, not manufacturing. The most common subject is unlawful sale of unapproved and misbranded drugs to US consumers, at 54 letters, followed by false and misleading claims. Only eight are about adulterated products from compounding pharmacies, and fewer than one in ten name adulterated drugs in their subject line at all.
No. It means the FDA told a company to fix something, and companies do fix things. A letter discloses a specific, dated, official objection, which is more useful than a rating, but it is not a finding that anyone was harmed.
Fifty-seven of the 157 letters are matched to a seller we review. They cover 57 sellers, run by 54 operating companies, and five of those sellers have since closed. That is roughly one in eleven of the sellers we list.
Yes. Four seller reviews stated they had four, five or six warning letters when none of those companies had any letter in the register. The count had been built from a field that also held general FDA notes. It is corrected and guarded, and we verified the fix did not create the opposite error.
Correction (September 2026): this article previously counted 186 letters, 109 of them in 2025, with 87 about unlawful sale. Thirty-eight letters had been entered in our register twice (the thirty-eighth, a MyStart Health letter, was found on September 30). The corrected figures at the time were 148 letters, 71 in 2025 and 54 about unlawful sale; letters added to the register since account for the 157 above. The conclusion is unchanged.

References

  1. 1.GLP Watchdog. FDA warning letter register — 157 letters relevant to GLP-1 selling and compounding, each linked to its FDA source; counts computed September 30, 2026 GLP Watchdog register. 2026. https://glpwatchdog.org/fda-warning-letters
  2. 2.U.S. Food and Drug Administration Warning Letter to Online Generic Medicine/www.onlinegenericmedicine.com (MARCS-CMS 737806), September 23, 2026 FDA Warning Letters. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026
  3. 3.U.S. Food and Drug Administration Warning Letter to Cheap Medicine Shop/www.cheapmedicineshop.com (MARCS-CMS 737810), September 24, 2026 FDA Warning Letters. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026

What Cannot Legally Be Compounded, and Who Is Selling It Anyway

Federal law bars retatrutide and cagrilintide from compounding entirely. We checked our own 560-seller register against that rule, found 7 with it on the menu, and discovered our own reviews were not telling readers.

8 min read

BPC-157 FDA Status: What the Agency Put on the Record

Not approved, and not on the list of substances a 503A compounding pharmacy may use. FDA recorded specific concerns: immunogenicity, peptide impurities, and “no, or only limited, safety-related information”.

8 min read

CJC-1295 and Ipamorelin: What FDA Recorded

Sold as a stack for fat loss. FDA identified serious adverse events with CJC-1295 (increased heart rate and systemic vasodilatory reaction), and neither peptide has a weight-loss trial.

7 min read

What Makes a Telehealth GLP-1 Prescription Legitimate

The FDA publishes seven warning signs for telehealth medicine sellers. Here they are, with what proper prescribing looks like and the one disclosure that 139 of our 560 sellers failed in an August 2026 count.

7 min read

Is the Vial You Received What the Label Says?

FDA has found labels naming compounding pharmacies that do not exist, and labels naming real pharmacies that did not make the product. What to check when the box arrives, and what the 990 adverse event reports mean.

8 min read

Who Actually Runs Your GLP-1 Brand

At our August 2026 count, 61 of the 560 sellers we tracked named one of just seven shared entities: one white-label platform, two prescriber networks, four compounding pharmacies. Comparing two brands can mean comparing two markups on the same vial.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Gala

Moving between compounded and brand without changing seller

7.9

Luvo Health

Moving between compounded and brand without changing seller

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →